US2017080002A1PendingUtilityA1

Methods for providing sialylated oligosaccharides

33
Assignee: UNIV GRONINGENPriority: Dec 7, 2011Filed: Dec 2, 2016Published: Mar 23, 2017
Est. expiryDec 7, 2031(~5.4 yrs left)· nominal 20-yr term from priority
Inventors:Erik SallomonsMaarten Hotse WilbrinkPeter SandersJohannis Paulus KamerlingCatherina Anna Van VuureJohannes Adrianus Hage
A61P 33/02A61P 31/04A61P 1/00A23L 33/40A23K 20/163A61K 31/715A23K 50/60A23L 5/00A23K 50/10A23L 29/30A61K 31/702A23L 7/00C12P 19/26C12Y 302/01018C12P 19/00A23L 33/21A23K 50/30A23L 33/125C12P 19/14C12P 19/04C07H 3/06A23V 2002/00
33
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a method for providing analogs of human milk oligosaccharides (HMO), in particular oligosaccharides containing terminal sialic acid. The method comprises the steps of: a) providing a source of non-digestible galactooligosaccharides (GOS) containing at least two terminally bonded β-linked galactose residues; b) providing a sialic acid donor having (α2-3)-sialylated O-glycans; c) contacting said GOS with said sialic acid donor in the presence of an enzyme having trans-sialidase activity in an enzyme reaction mixture; and d) isolating from said enzyme reaction mixture a fraction comprising at least 20 percent by weight of disialylated galactooligosaccharides (di-Sia-GOS) based on the dry matter.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . A composition comprising at least 5 percent by weight of disialylated galactooligosaccharides, obtainable by a method comprising:
 a) providing a source of non-digestible galactooligosaccharides (GOS) containing at least two terminally bonded β-linked galactose residues;   b) providing a sialic acid donor having (α2-3)-sialylated O-glycans;   c) contacting said GOS with said sialic acid donor in the presence of an enzyme having trans-sialidase activity in an enzyme reaction mixture; and   d) obtaining from said enzyme reaction mixture a fraction comprising at least 5 percent by weight of disialylated galactooligosaccharides (di-Sia-GOS) based on the dry matter.   
     
     
         14 . Composition according to  claim 13 , comprising at least 7 wt %, of disialylated galactooligosaccharides. 
     
     
         15 . Composition according to  claim 13  comprising one or more di-Sia-GOS species selected from the group consisting of
 Neu5Ac(α2-3)Gal(α1-4)Glc(α1-1β)Gal(3-2α)Neu5Ac 
 Neu5Ac(α2-3)Gal(α1-2)[Neu5Ac(α2-3)Gal(β1-6)]Glc 
 Neu5Ac(α2-3)Gal(β1-3)[Neu5Ac(α2-3)Gal(β1-6)]Glc, 
 Neu5Ac(α2-3)Gal(β1-4)[Neu5Ac(α2-3)Gal(β1-6)]Glc 
 Neu5Ac(α2-3)Gal(β1-2)[Neu5Ac(α2-3)Gal(β1-4)]Glc 
 Neu5Ac(α2-3)Gal(β1-4)Gal(β1-4)Glc(α1-1β)Gal(3-2α)Neu5Ac 
 Neu5Ac(α2-3)Gal(α1-4)Glc(α1-1β)Gal(4-1β)Gal(3-2α)Neu5Ac 
 Neu5Ac(α2-3)Gal(α1-4)Gal(β1-4)Gal(β1-4)Glc(α1-1β)Gal(3-2α)Neu5Ac 
 Neu5Ac(α2-3)Gal(β1-4)Gal(β1-4)Glc(α1-1β)Gal(4-1β)Gal(3-2α)Neu5Ac 
 Neu5Ac(α2-3)Gal(β1-4)Glc(α1-1β)Gal(4-1β)Gal(4-1β)Gal(3-2α)Neu5Ac 
 Neu5Ac(α2-3)Gal(β1-4)Gal(β1-4)Gal(β1-4)Gal(β1-4)Glc(α1-1β)Gal(3-2α)Neu5Ac 
 Neu5Ac(α2-3)Gal(β1-4)Gal(β1-4)Gal(β1-4)Glc(α1-1β)Gal(4-1β)Gal(3-2α)Neu5Ac 
 Neu5Ac(α2-3)Gal(β1-4)Gal(β1-4)Glc(α1-1β)Gal(4-1β)Gal(4-1β)Gal(3-2α)Neu5Ac 
 Neu5Ac(α2-3)Gal(β1-4)Glc(α1-1β)Gal(4-1β)Gal(4-1β)Gal(4-1β)Gal(3-2α)Neu5Ac 
 
     
     
         16 . Composition according to  claim 13  for use as nutritional, pharmaceutical or nutraceutical additive. 
     
     
         17 . Nutritional product comprising a composition according to  claim 13 . 
     
     
         18 . Animal feed product comprising a composition according to  claim 13 . 
     
     
         19 . (canceled) 
     
     
         20 . A composition according to  claim 13 , for use in a method of treating or preventing an infection by a pathogen in a subject in need thereof. 
     
     
         21 . Composition according to  claim 20 , wherein the pathogen is a bacterium or protozoan. 
     
     
         22 . Composition according to  claim 20 , for treating or preventing amebiasis or necrotizing enterocolitis (NEC). 
     
     
         23 . Composition according to  claim 13 , comprising at least 10 wt % of disialylated galactooligosaccharides. 
     
     
         24 . Nutritional product comprising a composition according to  claim 17 , wherein said product is an infant formula. 
     
     
         25 . Animal feed product comprising a composition according to  claim 18 , wherein the feed product is formulated for piglets or calves. 
     
     
         26 . A composition according to  claim 20 , wherein said subject is a human subject. 
     
     
         27 . The composition according to  claim 26  wherein said human subject is an infant. 
     
     
         28 . The composition according to  claim 20 , wherein the pathogen is  Entamoeba histolytica.

Join the waitlist — get patent alerts

Track US2017080002A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.